retatrutide fda approval status 2025 approves this year? Predictions & Odds 2026 Retatrutide Weight Loss Results:Trial Data
Description
It is injected once a week Tirzepatide: A combination of GLP-1 and GIP agonists
The trials did not report higher rates of arrhythmia, heart failure, or other acute cardiac problems in retatrutide groups compared with placebo
Diabetes Res Clin Pract 174:108734
About 4% of GLP-1 users developed osteoporosis, compared with a little over 3% of nonusers an increased risk of about 30%
Lilly has harshly criticized the cheaper products made by compounding pharmacies going so far as to send cease-and-desist letters to telehealth sites offering compounded products
